Since dysregulated cell cycle regulation is considered one of the hallmarks of cancer, CDK inhibition for therapeutic purposes, especially CDK4/6 using small molecule inhibitors, presents a convincing solution for overcoming resistance to conventional drugs [75]. This evidence concerns the gene CDK4 and cancer.